Italia markets closed

Moderna, Inc. (MRNA)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
173,25-3,10 (-1,76%)
Alla chiusura: 04:00PM EST
173,35 +0,10 (+0,05%)
Dopo ore: 05:13PM EST
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente176,35
Denaro172,94 x 1100
Lettera173,25 x 1400
Min-Max giorno172,40 - 178,74
Intervallo di 52 settimane115,03 - 217,25
Media Volume5.109.280
Beta (5 anni mensile)1,71
Rapporto PE (ttm)6,48
EPS (ttm)26,74
Prossima data utili23 feb 2023
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A226,64
  • GlobeNewswire

    CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

    Collaboration will combine Moderna’s mRNA technology with CytomX’s Probody® Platform to generate and develop therapeutics for oncology and non-oncology conditions CytomX to receive $35 million upfront payment with the potential for additional research, milestone, and royalty payments SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ: CTMX), a leader in the field of conditionally activated oncology therapeutics and Moderna, Inc.

  • GlobeNewswire

    Moderna exercises option to license proprietary targeting technology from Autolus

    - Option exercised on undisclosed immune-oncology target following evaluation period by Moderna - - Autolus receives option exercise fee, with potential for development milestone payments plus royalties - LONDON, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programed T cell therapies, today announces that Moderna (MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vacc

  • GlobeNewswire

    Senti Bio Secures Additional Financing from Leaps by Bayer and Provides Update on Proposed Business Combination with Dynamics Special Purpose Corp. (DYNS)

    - Leaps by Bayer led Series B investment in Senti Bio in 2021; Additional Convertible Note financing expands committed capital to PIPE investment associated with previously announced Business Combination Agreement with DYNS - - DYNS announces effectiveness of registration statement on Form S-4 - - Meeting of DYNS stockholders to approve proposed business combination scheduled for Tuesday, June 7, 2022 at 10:00 a.m. ET - SOUTH SAN FRANCISCO, Calif., May 24, 2022 (GLOBE NEWSWIRE) -- Senti Bioscien